Paricalcitol
- Atc Codes:H05BX02
- CAS Codes:131918-61-1
- PHARMGKB ID:131918-61-1
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Substrate of
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Zemplar; Bulgaria: Zemplar; Czech Republic: Zemplar; Denmark: Zemplar; Estonia: Zemplar; Finland: Zemplar; Germany: Zemplar; Greece: Zemplar; Hungary: Zemplar; Ireland: Zemplar; Italy: Zemplar; Netherlands: Zemplar; Poland: Zemplar; Portugal: Zemplar; Romania: Zemplar; Slovakia: Zemplar; Slovenia: Zemplar; Spain: Zemplar; Sweden: Zemplar; UK: Zemplar.
North America
USA: Zemplar.
Latin America
Argentina: Zemplar; Mexico: Zemplar.
Drug combinations
Chemistry
Paricalcitol: C~27~H~44~O~3~. Mw: 416.64. (1) 19-Nor-1-α,25-dihydroxyvitamin D~2~; (2)(1α.3β,7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol; (3)(7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1α,3β,25-triol. CAS-131918-61-1 (1997).
Pharmacologic Category
Vitamins; Vitamin D. (ATC-Code: H05BX02).
Mechanism of action
A synthetic vitamin D analog which binds to and activates vitamin D receptor in kidney, parathyroid gland, intestine and bone, thus reducing parathyroid hormone levels and improving calcium and phosphate homeostasis.
Therapeutic use
Prevention and treatment of secondary hyperparathyroidism associated with stage 3, 4 and 5 chronic kidney disease.
Pregnancy and lactiation implications
Teratogenic effects not observed in animal studies. There are no adequate, well-controlled studies in pregnant women.
Unlabeled use
Contraindications
Hypersensitivity to paricalcitol or any component of the formulation. Evidence of vitamin D toxicity. Hypercalcemia.
Warnings and precautions
Excessive vitamin D administration may lead to over-suppression of PTH, progressive or acute hypercalcemia, hypercalciuria, hyperphosphatemia and adynamic bone disease. Progressive and/or acute hypercalcemia may increase risk of cardiac arrhythmias and seizures. Chronic hypercalcemia may lead to generalized vascular and other soft-tissue calcification. Use with caution in patients taking cardiac glycosides (digitalis toxicity potentiated by hypocalcemia).